“Isn’t it a shame we accept that each year millions of gallons of blood drain from critically ill people into waste bags?”
For further development of the technology, Haermonics is looking to cooperate with medical centers globally to substantiate the CPPF method and investigate its future use for targeted therapy. Haermonics is also looking for partners to develop the current prototype into a commercially viable product.
Chief Medical Officer
Clinical Trials Coordinator
“On the other hand, when our surgery causes blood to leave the vascular system, blood becomes a highly toxic and injurious agent itself. Isn’t it strange that we do not take the necessary and effective measurements to definitively clean up our operation site from this?” Dave Koolbergen
Haermonics is well funded for the near future. Seriously interested future investors are kindly asked to fill in below form with specific questions. Haermonics is about saving lives. Quality and transparency are key to reach are goals. We strive for quality and transparency in our communication with investors and shareholders.